Testing effectiveness (Phase 2)Study completedNCT00411749What this trial is testingV501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)Who this might be right forHPV Infections Merck Sharp & Dohme LLC 107
Testing effectiveness (Phase 2)Study completedNCT01461993What this trial is testingA Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17Who this might be right forVaccinesMeningococcal Vaccines Pfizer 2,499
Not applicableActive Not RecruitingNCT06197802What this trial is testingPlateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil®9 in Young WomenWho this might be right forCervical CancerCondylomata Acuminata Xiamen University 392
Post-approval studies (Phase 4)Active Not RecruitingNCT03943875What this trial is testingGARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd DoseWho this might be right forImmunizationEfficacyHuman Papilloma Virus The University of Texas Medical Branch, Galveston 767
Large-scale testing (Phase 3)Study completedNCT01304498What this trial is testingImmunogenicity and Tolerability of V503 Versus GARDASIL (V503-009)Who this might be right forHuman Papillomavirus Merck Sharp & Dohme LLC 600
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07339163What this trial is testingEfficacy of Booster Injection With Gardasil-9 Vaccine on Intersurgical Interval* for Adults With Recurrent Respiratory Papillomatosis*Who this might be right forRecurrent Respiratory Papillomatosis (RRP) Ohio State University 50
Large-scale testing (Phase 3)Study completedNCT03546842What this trial is testingSafety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)Who this might be right forPapillomavirus InfectionsUterine Cervical NeoplasmsVulvar Neoplasms+3 more Merck Sharp & Dohme LLC 201
Large-scale testing (Phase 3)UnknownNCT05668572What this trial is testingA Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV VaccineWho this might be right forHuman Papillomavirus Infection Beijing Health Guard Biotechnology, Inc 12,000
Early research (Phase 1)Study completedNCT00851643What this trial is testingBroad Spectrum HPV Vaccine Dose Escalation Study (V502-002)Who this might be right forHuman Papilloma VirusCervical CancerVulvar Cancer+2 more Merck Sharp & Dohme LLC 158
Large-scale testing (Phase 3)Study completedNCT03728881What this trial is testingSingle Dose of Cervarix Vaccine in Girls or Three Doses of Gardasil Vaccine in Women for the Prevention of Human Papillomavirus Infection, the PRIMAVERA-ESCUDDO TrialWho this might be right forHuman Papillomavirus-Related Cervical Carcinoma National Cancer Institute (NCI) 1,240
Post-approval studies (Phase 4)Study completedNCT01914367What this trial is testingStudy of the Molecular Mechanisms Underlying the Cross-neutralizing Capacity of AS04-adjuvanted HPV Vaccine (Cervarix®) in Comparison With the Aluminiumhydroxyphosphate Sulphate Adjuvanted HPV Vaccine (Gardasil®)Who this might be right forInfection With Human Papillomavirus University Hospital, Ghent 12
Large-scale testing (Phase 3)Study completedNCT04782895What this trial is testingImmunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of AgeWho this might be right forCervical CancerCondylomata Acuminata Xiamen University 488
Large-scale testing (Phase 3)Study completedNCT00813319What this trial is testingGirls OnGuard: HPV Vaccination Uptake Among African American Adolescent FemalesWho this might be right forVaccination Emory University 216
Large-scale testing (Phase 3)WithdrawnNCT00733122What this trial is testingTolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)Who this might be right forHPV Infections Merck Sharp & Dohme LLC
Not applicableStudy completedNCT00524745What this trial is testingImmunogenicity and Reactogenicity of Alternative Schedules of GardasilWho this might be right forDose Schedule Study PATH 903
Large-scale testing (Phase 3)Study completedNCT00423046What this trial is testingImmunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of AgeWho this might be right forInfections, PapillomavirusPapillomavirus Vaccines GlaxoSmithKline 1,106
Large-scale testing (Phase 3)Study completedNCT01862874What this trial is testingEfficacy and Tolerability Study of V501 in Japanese Males (V501-122)Who this might be right forAnogenital Human Papilloma Virus InfectionCondyloma Acuminata Merck Sharp & Dohme LLC 1,124
Post-approval studies (Phase 4)Active Not RecruitingNCT05557370What this trial is testingImmunogenicity of HPV Vaccine in Transplant Recipients.Who this might be right forChronic Kidney DiseasesKidney Transplant Medical College of Wisconsin 30
Early research (Phase 1)Ended earlyNCT00798265What this trial is testingA Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young AdultsWho this might be right forHuman Immunodeficiency VirusHuman Papillomavirus- 6, 11, 16, 18Adolescent+1 more National Cancer Institute (NCI) 26
Testing effectiveness (Phase 2)Not Yet RecruitingNCT03947775What this trial is testingHPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSILWho this might be right forAnal Intraepithelial NeoplasiaAnal CancerHuman Papilloma Virus University Health Network, Toronto 228